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of Myocardial Infarction at 6 Months
An OxAMI Study (Oxford Acute Myocardial Infarction)Niket Patel, MBBS, BSC,* Ricardo Petraco, MBBS,y Erica Dall’Armellina, MD,z George Kassimis, MD, MSC, PHD,*
Giovanni Luigi De Maria, MD,* Sam Dawkins, MBBS,x Regent Lee, MBBS, DPHIL,x Bernard D. Prendergast, MD,*
Robin P. Choudhury, DM,z John C. Forfar, MD, PHD,* Keith M. Channon, MD,x Justin Davies, MBBS, BSC, PHD,y
Adrian P. Banning, MBBS, MD,* Rajesh K. Kharbanda, MBCHB, PHD*xABSTRACTOBJECTIVES The aim of this study was to deﬁne which measure of microvascular best predicts the extent of left
ventricular (LV) infarction.
BACKGROUND Microvascular injury after ST-segment elevation myocardial infarction (STEMI) is an important
determinant of outcome. Several invasive measures of the microcirculation at primary percutaneous coronary inter-
vention (PPCI) have been described. One such measure is zero-ﬂow pressure (Pzf), the calculated pressure at which
coronary ﬂow would cease.
METHODS In 34 STEMI patients, Pzf, hyperemic microvascular resistance (hMR), and index of microcirculatory
resistance (IMR) were derived using thermodilution ﬂow/pressure and Doppler ﬂow/pressure wire assessment of
the infarct-related artery following PPCI. The extent of infarction was determined by blinded late gadolinium
enhancement on cardiac magnetic resonance at 6 months post-PPCI. Infarction of $24% total LV mass was used
as a categorical cutoff in receiver-operating characteristic curve analysis.
RESULTS Pzf was superior to both hMR and IMR for predicting $24% infarction area under the curve: 0.94 for Pzf
versus 0.74 for hMR (p ¼ 0.04) and 0.54 for IMR (p ¼ 0.003). Pzf $42 mm Hg was the optimal cutoff value, offering
100% sensitivity and 73% speciﬁcity. Patients with Pzf $42 mm Hg also had a lower salvage index (61.3  8.1 vs. 44.4 
16.8, p ¼ 0.006) and 6-month ejection fraction (62.4  3.6 vs. 49.9  9.6, p ¼ 0.002). In addition, there were sig-
niﬁcant direct relationships between Pzf and troponin area under the curve (rho ¼ 0.55, p ¼ 0.002), ﬁnal infarct mass
(rho ¼ 0.75, p < 0.0001), percentage of LV infarction and percent transmurality of infarction (rho ¼ 0.77 and 0.74,
respectively, p < 0.0001), and inverse relationships with myocardial salvage index (rho ¼ 0.53, p ¼ 0.01) and 6-month
ejection fraction (rho ¼ 0.73, p ¼ 0.0001).
CONCLUSIONS Pzfmeasured at the time of PPCI is a better predictor of the extent ofmyocardial infarction than hMR or IMR.
Pzf may provide important prognostic information at the time of PPCI and merits further investigation in clinical studies with
relevant outcomemeasures. (JAmColl Cardiol Intv 2015;8:1410–21)©2015by theAmericanCollege of CardiologyFoundation.
AB BR E V I A T I O N S
AND ACRONYM S
AUC = area under the curve
CMR = cardiac magnetic
resonance
ECG = electrocardiographic/
electrocardiogram
EF = ejection fraction
hMR = hyperemic
microvascular resistance
IMR = index of microcirculatory
resistance
IRA = infarct-related artery
LGE = late-gadolinium
enhancement
LV = left ventricular
MBG = myocardial blush grade
MVO = microvascular
obstruction
Pa = aortic pressure
Pd = distal pressure
PPCI = primary percutaneous
coronary intervention
PV = peak velocity
Pzf = zero-ﬂow pressure
ROC = receiver-operating
characteristic
STEMI = ST-segment elevation
myocardial infarction
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1411P rimary percutaneous coronary intervention(PPCI) is the most effective reperfusion ther-apy for ST-segment elevation myocardial
infarction (STEMI) (1,2). Although infarct-related ar-
tery (IRA) patency is achieved in a large majority,
more than one-half of cases have angiographic
or electrocardiographic (ECG) evidence of microvas-
cular no-reﬂow, which is associated with worse out-
comes (3). Several invasive parameters have been
investigated to determine their value in assessment
of the microcirculation, and prediction of the
extent of myocardial infarction after PPCI, including
zero-ﬂow pressure (Pzf), the index of microcircula-
tory resistance (IMR), and hyperemic microvascular
resistance index (hMR) (4–7). These parameters
have not been directly compared in the same pa-
tient cohort.
Pzf is the distal coronary pressure when theoreti-
cally the ﬂow in a coronary artery would cease. It is
not possible to measure this directly as in vivo coro-
nary ﬂow does not cease under normal circumstances
and so Pzf is extrapolated from pressure–velocity
loops. Pzf is signiﬁcantly higher than simply the point
at which driving pressure falls to outlet pressure (i.e.,
coronary sinus pressure). Although hyperemia re-
duces Pzf, it is still considerably higher than outlet
pressure principally due to microvascular tone/resis-
tance, which is abnormally raised in microvascular
dysfunction (8).
Cardiac magnetic resonance (CMR) imaging pro-
vides accurate and reproducible quantiﬁcation of the
extent of myocardial infarction. Left-ventricular (LV)
infarction $24% of overall LV mass, the degree
of transmural infarction, and ejection fraction
(EF) <50% are independent predictors of mortality
(9–12). Deﬁning a measure available at the time of
PPCI that predicts clinical outcome would provide
support in its use as measure of the efﬁcacy of
reperfusion, and to guide therapeutic interventions.
However, the optimal index from the measures
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compare directly the ability of Pzf, hMR, and
IMR to predict the extent of myocardial
infarction after STEMI, and to identify the
optimal threshold value for the most power-
ful parameter.
METHODS
PATIENT POPULATION. Thirty-seven pa-
tients undergoing PPCI for STEMI were
recruited from 131 primary PCI calls (Figure 1).
Diagnosis of STEMI required chest pain last-
ing longer than 30 min, within 12 h from
onset of symptoms, and ST-segment eleva-
tion of $2 mm (0.2 mV) in at least 2 contig-
uous leads on ECG and TIMI (Thrombolysis In
Myocardial Infarction) ﬂow grade 0 on initial
angiography. Exclusion criteria were presen-
tation with cardiogenic shock, previous
myocardial infarction, and previous cardiac
surgery. Verbal consent was obtained at the
time of PPCI, but an approved process was
applied because: 1) the treatment needs to be
given urgently; 2) it is necessary to take the
action for the purpose of the research ur-
gently; but 3) it is not reasonably practicable
to consult before enrolling the patient (Sec-
tion 32(9) of the Mental Capacity Act). The
research study, including risks and beneﬁts, were
discussed. The patient was given the choice to
participate or withdraw from the study at any time. In
accordance with the Mental Capacity Act and the
study protocol, a trained independent patient advo-
cate witnessed patient enrollment. Full written
informed consent was deferred until such time that
the subject had adequate time to process verbal and
written information. The study protocol and consent
process was approved by the National Research Ethics
Service Committee South Central Oxford (REC refer-
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FIGURE 1 Study CONSORT Diagram
CONSORT diagram of enrollment and ﬂow of patients through the study protocol. CABG ¼ coronary artery bypass graft; CMR ¼ cardiac
magnetic resonance; CS ¼ cardiogenic shock; IRA ¼ infarct-related artery; ISR ¼ in-stent restenosis; NSTEMI ¼ non–ST-segment elevation
myocardial infarction; OxAMI ¼ Oxford Acute Myocardial Infarction; PPCI ¼ primary percutaneous coronary intervention; STE ¼ ST-segment
elevation; STEMI ¼ ST-segment elevation myocardial infarction; TIMI ¼ Thrombolysis In Myocardial Infarction.
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1412STUDY PROTOCOL. All patients received a stan-
dardized protocol of clopidogrel (600 mg) and aspirin
(300 mg) loading before PPCI and were treated with
intravenous heparin and/or bivalirudin during the
procedure. Coronary catheterization and interven-
tion were performed using a 6-F guiding catheter via
radial access. Epicardial coronary reperfusion was
established with a thrombus aspiration catheter with
or without lesion pre-dilation. Central venous access
was obtained using the femoral vein. All patients
received intracoronary glyceryl trinitrate (0.5 mg to
2 mg total over a variable number of boluses), drug-
eluting stent deployment, and dual antiplatelet
therapy with aspirin and clopidogrel for 1 year.
Appropriate secondary prevention was commen-
ced with statins, angiotensin-converting enzymeinhibitors and beta-blockers. Venous blood sampling
was performed for troponin calculation at PPCI, 6, 12,
and 24 h post-intervention.
INVASIVE CORONARY PHYSIOLOGY MEASURES
AND ANALYSIS. Indices of coronary physiology of
the IRA were assessed immediately following coro-
nary stenting at PPCI. Single measures were obtained.
Aortic pressure (Pa) was recorded from the guiding
catheter. IMR was deﬁned as the mean distal pressure
multiplied by the mean hyperemic transit time as
previously described (7,13), and obtained using a
coronary PressureWire (St. Jude Medical, St. Paul,
Minnesota). A dual sensor pressure and Doppler ﬂow-
velocity guidewire (ComboWire, Volcano Corpora-
tion, Rancho Cordova, California) was used to
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1413determine hMR and Pzf. Following calibration and
equalization with aortic pressure, the guidewire was
placed distal to the stented lesion, and small rota-
tional movements made to produce the most-dense
Doppler envelope. Simultaneous ECG, Pa, distal
pressure (Pd) and instantaneous peak velocity (PV)
recordings were obtained using the ComboMap Pres-
sure and Flow System (Volcano Corporation) at
baseline and at hyperemia induced by a 140 mg/kg/
min intravenous infusion of adenosine. Recordings
were transferred for ofﬂine analysis. Recordings of 5
to 15 consecutive cycles at baseline and at hyperemia
were identiﬁed, and source data for instantaneous Pd
and PV were exported using ComboMap Study
Manager (Volcano Corporation). These data were
analyzed using custom software packages designed
on MATLAB (MathWorks, Natick, Massachusetts).
Average Pd, Pa, and PV of consecutive beats at rest
and during hyperemia were used to calculate hMR
(deﬁned as the ratio of average Pd and average PV
during hyperemia) (14). Pzf was determined using
automated algorithms developed on MATLAB. Data
from several cardiac cycles during hyperemia were
used to construct ensembled average Pd and PV
against time plots (Figure 2A). The automated algo-
rithm then determined the mid-diastolic period of the
averaged cardiac cycle (Figure 2B), and sampled this
diastolic phase (shown in black on Figure 2B and
Figure 2C) of the resultant pressure–velocity loop.
A line of regression is drawn automatically from the
diastolic data points, and Pzf is the pressure at which
this line crosses the x-axis (15). This is the extrapo-
lated distal coronary pressure at which ﬂow would
cease in the IRA.
ANGIOGRAPHIC ASSESSMENT. Coronary ﬂow was
graded using the standard TIMI criteria (16). Myocar-
dial blush grade (MBG) at the end of the procedure was
evaluated according to van’t Hof (17). Angiographic
no-reﬂow was deﬁned as TIMI ﬂow grade <3 and/or
TIMI ﬂow grade 3 with MBG <2 at completion of the
procedure. Two interventional cardiologists blinded to
clinical and outcome parameters performed the
angiographic analyses, and differences were resolved
by consensus. Quantitative blush evaluator software
(QuBE; open source) assessment was performed as
described previously (18,19).
ELECTROCARDIOGRAPHIC ANALYSIS OF ST-SEGMENT
RESOLUTION. For assessment of pre-procedural
ST-segment elevation the ECG with the maximal
ST-segment elevation (performed by paramedics or in
the emergency department) was taken. For post-
procedural ST-segment analysis, an ECG was recor-
ded 60 min after PPCI. Two readers blinded to clinicaland outcome parameters performed measurements.
The absolute level of ST-segment elevation was
measured with digital calipers to the nearest 0.01 mV,
20 ms after the end of the QRS interval. The sum of
pre-procedural and post-procedural ST-segment
elevation was calculated for anterior (leads V1 to V6,
I, and aVL) and non-anterior (leads II, III, aVF, V5, V6)
infarctions. For statistical analysis, summed ST-
segment resolution parameters were categorized as
complete ($70%) and incomplete (<70%).
TROPONIN ANALYSIS. Cardiac troponin I was quan-
tiﬁed using an automated chemiluminescent immu-
noassay technique, and the area under the curve
(AUC) was calculated using the trapezoidal method.
CMR IMAGE ACQUISITION AND ANALYSIS. All pa-
tients were examined at rest with a 3.0-T CMR scan-
ner (either MAGNETOM TIM-Trio or MAGNETOM
Verio, Siemens Healthcare, Erlangen, Germany) using
a phased-array 32-channel coil. Patients were scan-
ned on day 2 (n ¼ 26) and again at 6 months post-PPCI
(n ¼ 23; 3 patients withdrew consent). Identical short-
axis images at matching slice position with functional
images were acquired using steady-state free pre-
cession for cine imaging, T2-prep steady-state free
precession single-shot sequence with coil signal in-
tensity correction for edema imaging, and T1-
weighted segmented inversion-recovery gradient
echo-phase sensitive-inversion recovery sequence for
late-gadolinium enhancement (LGE) imaging as pre-
viously described. LGE images were acquired 15 min
after administration of 0.1 mmol/kg gadodiamide
contrast agent (Omniscan, GE Healthcare, Amersham,
United Kingdom) and analyzed following adjustment
of the inversion time to optimize nulling of remote
normal myocardium (20). CMR image analysis was
performed using certiﬁed software (cmr42, Circle
Cardiovascular Imaging, Calgary, Alberta, Canada).
For objective quantiﬁcation of both edema and LGE, a
reference region of interest was placed in remote
myocardium. The signal intensity threshold indi-
cating edema/LGE was imposed 2 standard deviations
above the mean intensity of the reference region of
interest (21). Microvascular obstruction (MVO) was
included in the measurement of edema and LGE.
MVO was quantiﬁed by manual delineation of hypo-
dense areas within LGE (22,23) and expressed as
percentage fraction of area at risk. The Myocardial
Salvage Index was deﬁned as the difference between
the area of edema at day 2 and the ﬁnal infarct size
assessed by LGE at 6 months. The standard American
Heart Association 17-segment model was used to
determine the IRA subtended myocardium, and
average values of wall thickness, thickening, motion,
FIGURE 2 Computer Algorithm for Determination of Pzf
(A) Assembled average of several cardiac cycles. (B) Automated determination of the diastolic period (in black). (C) Determination of zero-ﬂow
pressure (Pzf) by construction of a pressure–velocity loop and linear regression of the diastolic segment of the cardiac cycle (in black). Output
of this automated process is the pressure at zero ﬂow (x-axis intercept). Pd ¼ diastolic pressure.
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1414edema, and transmurality of infarction (LGE) are
presented for IRA territories (apical segments were
excluded from analysis due to motion artefact and
considerable variability in blood supply) (24).
STATISTICAL METHODS. Normally distributed met-
rics are reported as mean  SD, and the Student t test
used for comparisons. Nonparametric distributions
are reported as median (interquartile range), and theMann-Whitney test used for unpaired data. The
Fisher exact chi-square test was used for binary
variables. Correlations between continuous variables
were made using the Spearman rho correlation.
Receiver-operating characteristic (ROC) curves were
compared using the Delong method, and a p value
of <0.05 was considered statistically signiﬁcant (25).
ROC analyses were performed on MedCalc 13.2.1.0
(Ostend, Belgium). The Youden index was used to
TABLE 1 Clinical Characteristics of the Study Population, N ¼ 34
Presentation Age, yrs 61.0  10.6
Male 26 (76.5%)
Pain-to-balloon time, h 2.9 (1.9–4.6)
Door-to-balloon time, min 22 (17–34)
Systolic/diastolic BP mm Hg 125/79  25/21
Heart rate, beats/min 80  18
Coronary risk factors Dyslipidemia 18 (52.9%)
Current smoker 14 (41.2%)
Ex-smoker 16 (47.1%)
Diabetes mellitus 2 (5.9%)
Hypertension 11 (32.4%)
BMI 28.0  4.0
Procedural antithrombotic Unfractioned heparin 23 (67.6%)
Bivalirudin 32 (94.1%)
Abciximab 0 (0.0%)
IRA LAD 18 (52.9%)
LCX 2 (5.9%)
RCA 12 (35.3%)
OM 1 (2.9%)
Intermediate 1 (2.9%)
APPROACH JS 31.8 (26.7–51.0)
PCI characteristics Radial approach 34 (100.0%)
Thrombectomy device use 32 (94.1%)
Direct stenting 5 (14.7%)
Drug eluting stent use 30 (88.2%)
Stented segment length 20.0 (20.2–25.0)
Post-dilation 19 (55.9%)
Post-PCI outcomes TIMI ﬂow grade III 26 (76.5%)
MBG II or III 24 (70.6%)
Angiographic reﬂow 23 (67.6%)
APVresting, cm/s
1 23.0  10.9
APVhyperemia, cm/s
1 28.6  10.2
Pdresting, mm Hg 88  15
Pdhyperemia, mm Hg 72  16
Doppler CFR 1.4  0.6
Thermodilution CFR 1.9  1.1
Pzfresting, mm Hg 46.5  21.6
Pzfhyperemia, mm Hg 44.8  20.1
IMR 28.6 (20.0–43.5)
hMR 2.32 (2.01–3.54)
Values are mean  SD, median (interquartile range), or n/N (%). Angiographic reﬂow was deﬁned
as TIMI III and MBG $II.
APPROACH JS ¼ Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease
jeopardy score; APV ¼ average peak velocity; BMI¼ body mass index; BP¼ blood pressure; CFR¼
coronary ﬂow reserve; hMR ¼ hyperemic microvascular resistance; IMR ¼ index of microcircula-
tory resistance; IRA ¼ infarct-related artery; LAD ¼ left anterior descending coronary artery;
LCX ¼ left circumﬂex coronary artery; MBG ¼ myocardial blush grade; OM ¼ obtuse marginal;
PCI ¼ percutaneous coronary intervention; Pd ¼ diastolic pressure; Pzf ¼ zero-ﬂow pressure;
RCA ¼ right coronary artery; TIMI ¼ Thrombolysis In Myocardial Infarction.
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1415identify the ideal cutoff values from ROC curves. For
multiple testing, the Benjamini and Hochberg method
of type 1 error control was applied, and a p value
of <0.01 was considered statistically signiﬁcant (26).
All tests were 2-tailed. All other statistics were per-
formed on SPSS version 22.0 (IBM, Chicago, Illinois),
and ﬁgures were generated with GraphPad Prism 6.0
(GraphPad Software, La Jolla, California).
RESULTS
A total of 37 patients were recruited. Pzf could not be
measured in 3 patients due to poor Doppler enve-
lopes. Data from 34 patients were analyzed. The
baseline characteristics of the cohort are presented
in Table 1. Approximately one-half of the patients
underwent PPCI to the left anterior descending cor-
onary artery, approximately two-thirds achieved
angiographic reﬂow at the end of the procedure,
and the mean percent of LV ﬁnal infarction was
24.3  12.6%.
RELATIONSHIPS OF INVASIVE PARAMETERS OF
MICROVASCULAR FUNCTION TO ANGIOGRAPHIC,
ST-SEGMENT RESOLUTION, BIOCHEMICAL, AND
CMR IMAGING MEASURES.
1. Relationships of Pzf to angiographic, ST-segment
resolution, biochemical, and CMR imaging param-
eters: Pzf was signiﬁcantly lower in those with
MBG >II (39.4  16.9 mm Hg vs. 59.4  22.8 mm Hg,
p ¼ 0.01). Furthermore, it correlated with both ST-
segment resolution (rho ¼ 0.64, p ¼ 0.001) and
troponin AUC (rho ¼ 0.55, p ¼ 0.002). There were
signiﬁcant direct relationships between Pzf and
MVO mass (rho ¼ 0.49, p ¼ 0.02), ﬁnal infarct mass
(rho ¼ 0.75, p < 0.0001), percentage of LV infarc-
tion and percent transmurality of infarction (rho ¼
0.77 and 0.74, respectively, p < 0.0001), and
inverse relationships with myocardial salvage in-
dex (rho ¼ 0.53, p ¼ 0.01) and 6-month EF
(rho ¼ 0.73, p ¼ 0.0001) (Figure 3).
2. Relationships of IMR to angiographic, ST-segment
resolution, biochemical, and CMR imaging param-
eters: In contrast to Pzf, IMR was no different in
those with MBG >II (20.2 [4.8 to 67.3] vs. 34.6 [23.0
to 65.1], p ¼ 0.10). There were no signiﬁcant
relationships between IMR and ST-segment reso-
lution (rho ¼ 0.27, p ¼ 0.15) or troponin AUC
(rho ¼ 0.24, p ¼ 0.2) and also no signiﬁcant
relationships between IMR and MVO mass, ﬁnal
infarct mass, percentage of LV infarction, percent
transmurality of infarction, or to myocardial
salvage index. Additionally, there were no signiﬁ-
cant differences in ECG, biochemical, or imagingparameters of infarction when the cohort was
stratiﬁed based on the previously reported IMR
prognostic cutoff of 40 (7).
3. Relationships of hMR to angiographic, ST-segment
resolution, biochemical, and CMR imaging param-
eters: hMR was not signiﬁcantly different in
those with MBG >II (2.2 [1.9 to 3.1] vs. 2.5 [2.2
to 3.9], p ¼ 0.69). However, there were no
FIGURE 3 Pzf Correlations With CMR Measures of Outcomes
Correlations between zero-ﬂow pressure (Pzf) and infarct size as a percentage of left ventricular (LV) mass (A), percentage transmurality
of infarction (B), salvage index (C), and ejection fraction (EF) (D) at 6 months post-presentation. CMR ¼ cardiac magnetic resonance;
Cx ¼ circumﬂex coronary artery; LAD ¼ left anterior descending coronary artery; RCA ¼ right coronary artery.
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1416signiﬁcant relationships to ST-segment resolution
(rho ¼ 0.31, p ¼ 0.09) or troponin AUC (rho ¼ 0.36,
p ¼ 0.05). There were signiﬁcant relationships with
ﬁnal infarct mass (rho ¼ 0.47, p ¼ 0.03), percentage
of LV infarction and percent transmurality of
infarction (rho ¼ 0.54 and 0.48, p ¼ 0.009 and
0.02, respectively), but myocardial salvage index
failed to reach signiﬁcance (rho ¼ 0.39, p ¼ 0.08).
There was, however, a close inverse relationship to
6-month EF (rho ¼ 0.62, p ¼ 0.002). Stratifying
the cohort based on a previously reported cutoff
value of $3.25 (4) identiﬁed a group with signiﬁ-
cantly higher troponin AUC (2,586 [2,035 to 5,070]
vs. 4,522 [2,973 to 9,272]; p ¼ 0.04), larger per-
centage of infarction (19.7  11.2% vs. 33.0  10.8%,
p ¼ 0.01), and lower EF at 6 months (58.7  7.5% vs.
45.2  8.4%, p ¼ 0.004).
In summary, Pzf and hMR are related to biochemical
and imaging assessments of infarction, and Pzf was
also inversely related to salvage index.CONSTRUCTION OF RECEIVER-OPERATING CHAR-
ACTERISTIC CURVE ANALYSIS. ROC curve analysis
was used to compare the performance of the coronary
physiology parameters (Pzf, hMR, and IMR) to pre-
dict: 1) $24% LV infarction; 2) $50% transmural
myocardial infarction; 3) <70% ST-segment resolu-
tion; and 4) $50% LVEF at 6 months.
1. Predicting $24% LV infarction at 6 months: The
AUC were 0.94 (p < 0.0001) for Pzf, 0.54 (p ¼ 0.77)
for IMR, and 0.74 (p ¼ 0.04) for hMR (Figure 4A).
Direct comparison of the AUC conﬁrmed that Pzf
was signiﬁcantly better than hMR (p ¼ 0.04) and
IMR (p ¼ 0.003). The optimal cutoff for
predicting $24% of LV infarction was $42 mm Hg,
with a sensitivity of 100% and speciﬁcity 73%.
2. Predicting $50% transmural myocardial infarction
at 6 months: The AUC were 0.94 (p < 0.0001) for
Pzf, 0.62 (p ¼ 0.30) for IMR, and 0.74 (p ¼ 0.04) for
hMR (Figure 4B). Direct comparison of the AUC
conﬁrmed that Pzf was signiﬁcantly better than
FIGURE 4 ROC Curves for Prediction of Parameters of Myocardial Infarction and Function
Receiver-operating characteristic (ROC) curves for zero-ﬂow pressure (Pzf), hyperemic microvascular resistance (hMR), and index of micro-
circulatory resistance (IMR) in predicting infarct size as a percentage of left ventricular (LV) mass$24% (A),$50% percentage transmurality of
infarction (B), $70% ST resolution (C), and normal ejection fraction (deﬁned as $50%) (D) at 6 months. AUC ¼ area under the curve.
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1417IMR (p ¼ 0.02). The optimal cutoff for predicting
>50% transmural LV infarction was $50 mm Hg. A
threshold value of $42 mm Hg (optimal for $24%
of LV infarction) returns a sensitivity of 100% and
speciﬁcity 67%.
3. Predicting $70% ST-segment resolution: The AUC
were 0.88 (p < 0.0001) for Pzf, 0.62 (p ¼ 0.26)
for IMR, and 0.71 (p ¼ 0.04) for hMR (Figure 4C).
Direct comparison of the AUC conﬁrmed that Pzfwas signiﬁcantly better than IMR (p ¼ 0.02). The
optimal cutoff for predicting $70% ST-segment
resolution was #43 mm Hg. A value of <42 mm Hg
returns a sensitivity of 61% and speciﬁcity 92%.
4. Predicting LVEF at 6 months (deﬁned as $50%):
The AUC were 0.87 (p < 0.0001) for Pzf, 0.77
(p ¼ 0.04) for hMR, and 0.71 (p ¼ 0.14) for IMR
(Figure 4D). The optimal cutoff for predicting EF
$50% was #49 mm Hg (sensitivity 80%, speciﬁcity
TABLE 2 Clinical, Angiographic, Physiological, And Imaging Parameters in Patients
Stratiﬁed by Pzf Value of 42 mm Hg
Pzf at PPCI
p Value
<42 mm Hg
(n ¼ 14)
$42 mm Hg
(n ¼ 20)
Clinical
Age, yrs 62.4  11.2 59.9  10.2 0.50
Male 11/14 (78.6%) 15/20 (75.0%) 0.81
Ischemia time, h 2.5 (1.9–7.6) 3.0 (1.9–3.9) 0.99
First heart rate, beats/min 70 (70–80) 80 (70–100) 0.10
Systolic BP, mm Hg 122.4  27.6 127.0  24.6 0.63
Diastolic BP, mm Hg 71.6  24.7 83.9  16.3 0.10
Door to balloon time, h 20.0 (17.0–29.0) 24.0 (18.3–82.8) 0.57
Percentage ST-segment
resolution
85.6  19.8 67.3  15.7 0.009
Troponin AUC 2,040 (839–3,119) 4,991 (3,080–7,341) 0.02
Angiographic
LAD territory 5/14 (35.7%) 13/20 (65.0%) 0.09
APPROACH JS 28.8 (26.4–37.3) 39.2 (31.0–51.0) 0.09
TIMI ﬂow grade 3 13/14 (92.9%) 13/20 (65.0%) 0.10
MBG III 9/14 (64.3%) 3/20 (15.0%) 0.005
QuBE 15.5  5.4 10.5  3.7 0.003
Physiology
FFR 0.95  0.04 0.95  0.05 0.92
IMR 24.4 (14.2–40.7) 33.8 (22.0–46.4) 0.20
hMR 2.07 (1.87–2.48) 2.65 (2.12–4.49) 0.03
Pzf 28.1  13.6 56.5  15.1 <0.0001
CMR
At day 2
Myocardial edema, g 29.4  14.4 47.7  19.1 0.04
Myocardial edema, % of LV 33.6  11.6 51.9  16.3 0.02
MVO mass, g 0.0 (0.0–0.9) 2.5 (0.0–3.7) 0.16
MVO, % of AAR 0.9 (0.0–3.0) 3.1 (0.0–5.9) 0.22
IRA territory wall edema, % 60.6 (48.2–67.5) 86.5 (70.7–92.7) 0.006
IRA territory wall motion, mm 6.0 (4.3–7.5) 3.1 (2.6–3.9) 0.001
IRA territory wall thickness, mm 8.0 (7.5–8.9) 8.4 (7.5–8.9) 1.00
IRA territory wall thickening, % 45.2  25.0 22.0  12.6 0.005
EDV, mm3 132.3  36.0 165.4  36.8 0.10
ESV, mm3 65.6  25.7 98.3  26.1 0.01
EF, % 53.5  8.9 40.9  5.5 <0.0001
At 6 months
Infarct mass, g 12.3 (4.9–15.6) 31.2 (21.1–39.4) 0.001
Infarct size, % of LV 13.0  6.0 30.3  11.0 <0.0001
Salvage index 61.3  8.1 44.4  16.8 0.006
Transmurality of infarction, % 26.4  14.5 55.3  18.5 0.001
IRA territory wall motion, mm 7.8  2.1 5.2  2.1 0.008
IRA territory wall thickness, mm 6.4  1.1 6.8  1.0 0.38
IRA territory wall thickening, % 67.7  20.0 40.0  28.1 0.02
EDV, mm3 133.6  22.9 178.5  26.8 0.001
ESV, mm3 52.1  11.7 90.4  26.8 0.001
EF, % 62.4  3.6 49.9  9.6 0.002
Values are mean  SD, median (interquartile range), or n (%). Statistically signiﬁcant p values using the Benjamini
and Hochberg method of type 1 error control are highlighted in bold.
AAR ¼ area at risk (edema CMR imaging); AUC ¼ area under the curve; CMR ¼ cardiac magnetic resonance
imaging; EDV ¼ end-diastolic volume; EF ¼ ejection fraction; ESV ¼ end-systolic volume; FFR ¼ fractional ﬂow
reserve; LV ¼ left ventricle; MVO ¼ microvascular obstruction; PPCI ¼ primary percutaneous coronary inter-
vention; other abbreviations as in Table 1.
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141886%). A value of <42 mm Hg returns a sensitivity
of 53% and speciﬁcity 100%.
CLINICAL CHARACTERISTICS OF PATIENTS WITH
Pzf ‡42 mm Hg. Twenty of 34 patients had Pzf $42
mm Hg (Table 2). This group had signiﬁcantly lower
ST-segment resolution, lower QuBE score, features of
adverse LV remodeling, and larger CMR myocardial
infarction. In addition, there was more extensive
transmural infarction and less recovery of IRA region
function as assessed by wall motion. This translated
to signiﬁcantly lower 6-month EF. Importantly, there
was also a signiﬁcantly lower salvage index.DISCUSSION
Our study has measured both thermodilution and
Doppler-based parameters of microvascular function
in the same cohort after STEMI and therefore allows
an important direct comparison of the utility of these
measures. We demonstrate that Pzf is the most sen-
sitive invasive coronary physiology index currently
available for the assessment of the microcirculation
at the time of PPCI for predicting the ﬁnal extent of
global and regional irreversible myocardial injury and
LV function at 6 months. It is signiﬁcantly better than
hMR and IMR. Pzf is also correlated to ECG charac-
teristics, biochemical markers, and imaging parame-
ters for ﬁnal infarct size and myocardial salvage
index.
There has been a longstanding interest in devel-
oping an understanding of the microcirculation after
STEMI, and advances in technology have allowed
measures to be developed for a number of important
physiological parameters in the context of contem-
porary PPCI. Both coronary ﬂow reserve (27,28) and
IMR have been used to assess altered microcircula-
tory states. Recently, IMR has gained attention due to
its perceived simpler methodology. A number of
studies have conﬁrmed that IMR measured at the
time of PPCI is an important predictor of infarct size
(5,6), and that using a categorical value of 40, allows
identiﬁcation of a group with adverse prognosis (7).
However, speciﬁc indices derived from combined
pressure/ﬂow data of the IRA vessel may provide
more detailed assessments of the microcirculation. In
2003, Shimada and colleagues (29) studied Pzf using a
Doppler wire and assessing arterial pressure from
the guiding catheter in patients undergoing PPCI
for anterior STEMI, and showed that Pzf corre-
lated with 18F-ﬂuorodeoxyglucose-positron emission
tomography delineated myocardial viability. In 2007,
Van Herck et al. (30) conﬁrmed that Pzf values were
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1419increased after myocardial infarction. More recently
hMR, Pzf, and Doppler coronary ﬂow reserve were
derived using a combined pressure/ﬂow wire in
27 patients after anterior STEMI (4). All measures
correlated with peak creatinine kinase-myocardial
band and CMR measures of infarct size, and Pzf was
found to be higher in those with >75% infarct trans-
murality. However, CMR was performed early after
infarction at only 13 days, and although LGE soon
after infarction may predict ﬁnal infarct size several
weeks to months later, it is preferable to determine
ﬁnal infarct size and LV function after maturation of
healing processes and remodeling (21,31,32).
Against this background of a series of studies
interrogating combined pressure/ﬂow data using
different methods and different outcomes, our cohort
was unselected on the basis of IRA and endpoints
were selected to relate to later prognosis. We also
used an automated algorithm for detection of the
analysis period for calculation of Pzf. Importantly,
this requires phasic signals of pressure and ﬂow for its
calculation, and cannot be calculated using thermo-
dilution systems that estimate mean ﬂow from transit
time across the entire cardiac cycle. It is likely that
the beneﬁt of Pzf is the exclusion of the systolic
portion from the calculation where resistance is
recognized to be highly variable due to ongoing wave
activity and the pressure–ﬂow relations are nonlinear.
We analyzed how these invasive parameters
predicted transmurality of infarction, ST-segment
resolution and 6-month EF. In each case, Pzf out-
performed hMR and IMR as demonstrated by the
greater area under the ROC curve. In our study, the
main endpoint was ﬁnal infarct size $24% of LV mass
on CMR. This value of infarct size has been shown to
be predictive of short-term mortality (9) and there-
fore offers a clinically relevant cutoff to test physio-
logical parameters. Additionally, it is the mean
percentage of LV infarction in our cohort. Pzf again
outperformed hMR and IMR in prediction of this
percentage infarct size.
A value of 42 mm Hg for Pzf was the optimal cutoff
for predicting $24% LV infarction. This categorical
approach selected a group with no signiﬁcant differ-
ence in the portion of left anterior descending
coronary artery infarctions, but lower ST-segment
resolution, larger troponin release, a larger area at
risk, lower 6-month EF, and signiﬁcantly lower
myocardial salvage index. The latter observation is
particularly relevant because it is clear that a larger
area at risk is associated with larger ﬁnal infarct size,
but the salvage index adjusts for this. Our data show
that Pzf can provide a measure at the time of PPCI,
that relates to salvage.STUDY LIMITATIONS. This was a small, single-center
study, but it is the ﬁrst study to directly examine
and compare the relationship and effects of
acute myocardial infarction on thermodilution and
Doppler/pressure-derived indices following PPCI. The
studied cohort may represent a selective group of
PPCI patients, but patients with TIMI ﬂow grade
0 were recruited, and the area at risk and APPROACH
(Alberta Provincial Project for Outcome Assessment in
Coronary Heart Disease) score both conﬁrmed that
the IRA subtended substantial myocardium, sug-
gesting that the study did not exclude those with
large myocardial infarctions. The results presented in
the preceding text are based on coronary pressure
and Doppler measurements taken after PPCI, and
maximal hyperemia may not be obtained. The use of a
fully automated technique to measure Pzf is
straightforward and independent of operator in-
ﬂuences. However, these analysis techniques are not
available for immediate results. As a consequence of
the small sample size, there is potential for a type 1
error affecting the results. However, the consistency
of the relationships and highly signiﬁcant p values
between Pzf and multiple important clinical outcome
measures suggest that these ﬁndings are of clinical
relevance. However, further investigation is justiﬁed
in order to deﬁne the clinical utility of Pzf and
improve our understanding of the microcirculation
after STEMI.
CONCLUSIONS
Microvascular reperfusion is only present in <50% of
patients, making it a potential therapeutic target. Our
study has shown that Pzf is a more sensitive measure
of microvascular function compared with IMR and
hMR, and therefore, may offer a means to identify
patients, at the time of PPCI, that would beneﬁt from
therapies directed at the microcirculation. Further-
more, this technique may allow objective measure-
ment of response to such future therapies that
may improve myocardial salvage and long-term
LV function.
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PERSPECTIVES
WHAT IS KNOWN? Following primary percutaneous
coronary intervention for STEMI more than one-half
of patients have impaired microcirculatory ﬂow, which
is associated with larger infarction and poorer out-
comes. Several invasive indices have been described to
assess the microcirculation, and we compared these
measures.
WHAT IS NEW? Our study demonstrates that Pzf is
signiﬁcantly better at predicting infarct size following
PPCI than hyperemic microvascular resistance or the
index of microcirculatory resistance. Assessment of
microcirculatory function following PPCI using Pzf allows
identiﬁcation of patients with adverse myocardial
recovery.
WHAT IS NEXT? Future investigations are needed to
fully understand its clinical utility in relationship to longer
term outcomes and as a technique to identify high risk
patients who may beneﬁt from alternative treatments.
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